USANA Health Sciences (NYSE:USNA) Rating Lowered to Strong Sell at Zacks Research

Key Points

• Zacks Research downgraded USANA Health Sciences to “strong sell” from “hold,” while other analysts have also issued negative ratings, giving the stock a consensus “sell” rating.
• USANA reported a quarterly loss of $0.07 per share and revenue of $223.27 million, missing estimates of $0.43 EPS and $235 million in revenue. The company’s FY2026 EPS guidance is $0.76, underscoring concerns about profitability and growth.
• USNA shares opened at $15.43, near their 52-week low of $14.35 and well below the 52-week high of $32.32; insiders have sold 13,869 shares worth approximately $261,441 over the past 90 days.

USANA Health Sciences (NYSE:USNA - Get Free Report) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating in a research note issued to investors on Thursday,Zacks.com reports.

USNA has been the topic of a number of other reports. Wall Street Zen downgraded USANA Health Sciences from a "buy" rating to a "hold" rating in a research report on Saturday. Weiss Ratings restated a "sell (d)" rating on shares of USANA Health Sciences in a report on Wednesday, June 24th. Two equities research analysts have rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of "Sell".

USANA Health Sciences Stock Performance

Shares of USNA opened at $15.43 on Thursday. The stock has a market capitalization of $284.84 million, a PE ratio of -12.75, a P/E/G ratio of 1.63 and a beta of 0.73. The company's fifty day moving average is $20.41 and its 200 day moving average is $19.66. USANA Health Sciences has a fifty-two week low of $14.35 and a fifty-two week high of $32.32.

USANA Health Sciences (NYSE:USNA - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of $0.43 by ($0.50). USANA Health Sciences had a positive return on equity of 3.41% and a negative net margin of 2.43%.The business had revenue of $223.27 million during the quarter, compared to analysts' expectations of $235.00 million. USANA Health Sciences has set its FY 2026 guidance at 0.760-0.760 EPS. As a group, research analysts forecast that USANA Health Sciences will post 0.76 earnings per share for the current year.

Insiders Place Their Bets

In other USANA Health Sciences news, Director John Turman Fleming sold 2,450 shares of the business's stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $17.93, for a total transaction of $43,928.50. Following the completion of the transaction, the director owned 4,230 shares in the company, valued at $75,843.90. The trade was a 36.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Brent Neidig sold 5,002 shares of the stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $19.45, for a total value of $97,288.90. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 13,869 shares of company stock valued at $261,441 over the last 90 days. Insiders own 0.82% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in USNA. AQR Capital Management LLC grew its stake in USANA Health Sciences by 82.8% in the 1st quarter. AQR Capital Management LLC now owns 21,845 shares of the company's stock worth $589,000 after acquiring an additional 9,894 shares in the last quarter. Empowered Funds LLC purchased a new stake in shares of USANA Health Sciences in the first quarter valued at approximately $687,000. Russell Investments Group Ltd. grew its stake in USANA Health Sciences by 31.4% in the second quarter. Russell Investments Group Ltd. now owns 13,377 shares of the company's stock worth $408,000 after purchasing an additional 3,198 shares in the last quarter. Quantbot Technologies LP grew its stake in USANA Health Sciences by 19.5% in the second quarter. Quantbot Technologies LP now owns 3,957 shares of the company's stock worth $121,000 after purchasing an additional 646 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership purchased a new position in USANA Health Sciences during the 2nd quarter worth $422,000. 54.25% of the stock is currently owned by institutional investors.

USANA Health Sciences News Roundup

Here are the key news stories impacting USANA Health Sciences this week:

• Positive Sentiment: Sidoti raised its estimates for Q3 2026 EPS to $0.11 from $0.09, Q1 2027 EPS to $0.34 from $0.31, and Q2 2027 EPS to $0.46 from $0.43. These revisions suggest some improvement in the analyst’s near-term outlook.
• Neutral Sentiment: Wall Street Zen lowered its stock rating on USANA, adding to uncertainty around the company’s outlook. USANA Health Sciences Stock Rating Lowered by Wall Street Zen
• Negative Sentiment: Sidoti’s broader revisions were substantially bearish: FY2026 EPS was cut to $0.76 from $2.12, FY2027 EPS to $1.77 from $2.77, and Q3 2026 EPS to $0.11 from $0.43 in the latest updates. The firm also reduced estimates for Q4 2026, Q1 2027, Q2 2027, and Q3 2027, although some of those forecasts were later partially raised.
• Negative Sentiment: The estimate cuts follow USANA’s latest quarterly results, in which the company reported a $0.07 per-share loss and revenue of $223.27 million, missing analyst expectations of $0.43 EPS and $235 million in revenue. The company’s FY2026 guidance remains just $0.76 EPS, reinforcing concerns about weak profitability and slowing business momentum.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company's portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA's products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source